Clinical Trial

A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Period

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate clinical efficacy and safety of arumakimig (MAS825) compared to placebo in patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) syndrome. In addition, the study will evaluate the long-term efficacy, safety and tolerability of arumakimig in this population.
Trial Details
NCT Number NCT07748624
Lead Sponsor Novartis Pharmaceuticals
Conditions VEXAS Syndrome
Enrollment 120 participants
Start Date 2026-10-30
Primary Completion 2028-12-26 (estimated)
Study Completion 2031-04-21 (estimated)
Updated on ClinicalTrials.gov 2026-08-06